Nombre del producto:(R)-6-tert-Butyl 4a-methyl 1-(4-fluorophenyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isoquinoline-4a,6(4H)-dicarboxylate

IUPAC Name:6-tert-butyl 4a-methyl (4aR)-1-(4-fluorophenyl)-1H,4H,4aH,5H,6H,7H,8H-pyrido[3,4-f]indazole-4a,6-dicarboxylate

CAS:864972-21-4
Fórmula molecular:C23H26FN3O4
Pureza:97%
Número de catálogo:CM227405
Peso molecular:427.48

Unidad de embalaje Stock disponible Precio($) Cantidad

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :864972-21-4
Fórmula molecular:C23H26FN3O4
Punto de fusión:-
Código de sonrisas:O=C([C@]12CC3=C(N(C4=CC=C(F)C=C4)N=C3)C=C1CCN(C(OC(C)(C)C)=O)C2)OC
Densidad:
Número de catálogo:CM227405
Peso molecular:427.48
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Column Infos

Relacorilant
Corcept completes enrollment in phase 3 Gradient trial of Relacorilant in patients with Adrenal Cushing’s Syndrome. Cushing's disease or hypercortisolism is a rare endocrine disorder that occurs when a pituitary adenoma makes excessive cortisol. Cortisol exerts its functions by binding to the glucocorticoid receptor (GR).
Relacorilant is a selective glucocorticoid receptor modulator (SGRM) in clinical development to prevent the effects of high cortisol. Relacorilant is being studied in various serious disorders, including ovarian, adrenal and prostate cancer and Cushing’s syndrome.